Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease

[1]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension global hypertension practice guidelines. , 2020, Journal of hypertension.

[2]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension Global Hypertension Practice Guidelines. , 2020, Hypertension.

[3]  Xin Gao,et al.  IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[5]  D. Semela,et al.  Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience. , 2019, Swiss medical weekly.

[6]  M. Allison,et al.  Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[7]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[8]  H. Tilg,et al.  Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease , 2018, Nature Reviews Gastroenterology & Hepatology.

[9]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[10]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[11]  A. Sanyal,et al.  Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis , 2017, Transplantation.

[12]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[13]  Herbert Tilg,et al.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.

[14]  D. S̆timac,et al.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? , 2016, World journal of gastroenterology.

[15]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[16]  E. Tapper,et al.  The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease , 2016, The American Journal of Gastroenterology.

[17]  T. Yamanaka,et al.  Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. , 2016, Gastroenterology.

[18]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[19]  Ling-jun Kong,et al.  Influence of Hepatic Inflammation on FibroScan Findings in Diagnosing Fibrosis in Patients with Chronic Hepatitis B. , 2015, Ultrasound in medicine & biology.

[20]  Q. Pan,et al.  Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[21]  H. Cao,et al.  Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. , 2014, World journal of gastroenterology.

[22]  Y. N. Park,et al.  Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) , 2011, Hepatology.

[23]  H. Chan,et al.  Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population , 2011, Journal of gastroenterology and hepatology.

[24]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[25]  B. Hillner,et al.  A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[26]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[27]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[28]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[29]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[30]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[31]  J. Widimský,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1998, Diabetes Care.

[32]  [Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[33]  Michael Roden,et al.  NAFLD and diabetes mellitus , 2017, Nature Reviews Gastroenterology &Hepatology.

[34]  최은희,et al.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). , 2011 .

[35]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[36]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[37]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.

[38]  A A Bravo,et al.  Liver biopsy. , 2001, The New England journal of medicine.